CRSP241018C35000
- 13.30
- +1.70+14.66%
CRISPR Therapeutics Newsroom
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
Cathie Wood's ARK Sheds Robinhood Stock, Adds to Amazon and Coinbase
CRISPR Therapeutics Deserves Its Lofty Valuation Even With Conservative Forecasts
RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating
Cathie Wood Stocks (CRSP, SHOP, SQ) Could Actually Be Darn Good Picks
With 66% Ownership of the Shares, CRISPR Therapeutics AG (NASDAQ:CRSP) Is Heavily Dominated by Institutional Owners
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Express News | Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older
CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Have Endured a 59% Loss From Investing in the Stock Three Years Ago
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Express News | CRISPR Therapeutics AG : Truist Securities Cuts Target Price to $100 From $120
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
BofA Upgrades Editas to Buy, Cites Reni-cel Progress